These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17430175)

  • 1. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
    Gonzalez-Rey E; Varela N; Chorny A; Delgado M
    Curr Pharm Des; 2007; 13(11):1113-39. PubMed ID: 17430175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D; Rodriguez R; Delgado M
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D; Delgado M
    Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M; Leceta J; Gomariz RP; Ganea D
    J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
    Gonzalez-Rey E; Delgado M
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
    Delgado M; Gonzalez-Rey E; Ganea D
    FASEB J; 2004 Sep; 18(12):1453-5. PubMed ID: 15231725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PACAP in immunity and inflammation.
    Delgado M; Abad C; Martinez C; Juarranz MG; Leceta J; Ganea D; Gomariz RP
    Ann N Y Acad Sci; 2003 May; 992():141-57. PubMed ID: 12794054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D; Delgado M
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression.
    Delgado M; Leceta J; Sun W; Gomariz RP; Ganea D
    Ann N Y Acad Sci; 2000; 921():68-78. PubMed ID: 11193881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
    Ganea D; Delgado M
    Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M; Ganea D
    J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M; Sun W; Leceta J; Ganea D
    J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors.
    Delgado M; Ganea D
    Arch Physiol Biochem; 2001 Oct; 109(4):372-6. PubMed ID: 11935376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis.
    Abad C; Waschek JA
    Curr Pharm Des; 2011; 17(10):1025-35. PubMed ID: 21524252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
    Delgado M; Leceta J; Ganea D
    J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.